SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

SANTA CRUZ BIOTECHNOLOGY, INC.

LRRC19 siRNA (m): sc-149058

BACKGROUND

LRRC19 (leucine-rich repeat-containing protein 19) is a 370 amino acid single-pass type I membrane protein that contains five LRR (leucine-rich repeats) and one LRRCT domain. The gene that encodes LRRC19 consists of approximately 12,558 bases and maps to human chromosome 9p21.2. Housing over 900 genes, chromosome 9 comprises nearly 4% of the human genome. Hereditary hemorrhagic telangiectasia, which is characterized by harmful vascular defects and familial dysautonomia, are both associated with chromosome 9. Mutations in DFNB31, located on human chromosome 9, are associated with Usher syndrome type 2, which is characterized by severe rod-cone dystrophy and varying degrees of hearing impairment. Notably, chromosome 9 encompasses the largest interferon family gene cluster.

REFERENCES

1. Burmeister, T., Schwartz, S., Taubald, A., Jost, E., Lipp, T., Schneller, F., Diedrich, H., Thomssen, H., Mey, U.J., Eucker, J., Rieder, H., Gökbuget, N., Hoelzer, D. and Thiel, E. 2007. Atypical Bcr-Abl mRNA transcripts in adult acute lymphoblastic leukemia. Haematologica 92: 1699-1702.
2. Ebermann, I., Scholl, H.P., Charbel Issa, P., Becirovic, E., Lamprecht, J., Jurklies, B., Millán, J.M., Aller, E., Mitter, D. and Bolz, H. 2007. A novel gene for Usher syndrome type 2: mutations in the long isoform of whirlin are associated with retinitis pigmentosa and sensorineural hearing loss. Hum. Genet. 121: 203-211.
3. Cottin, V., Dupuis-Girod, S., Lesca, G. and Cordier, J.F. 2007. Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler disease). Respiration 74: 361-378.
4. Chai, L., Dai, L., Che, Y., Xu, J., Liu, G., Zhang, Z. and Yang, R. 2009. LRRC19, a novel member of the leucine-rich repeat protein family, activates NFκB and induces expression of proinflammatory cytokines. Biochem. Biophys. Res. Commun. 388: 543-548.
5. Zeitz, M.J., Marella, N.V., Malyavantham, K.S., Goetze, S., Bode, J., Raska, I. and Berezney, R. 2009. Organization of the amplified type I interferon gene cluster and associated chromosome regions in the interphase nucleus of human osteosarcoma cells. Chromosome Res. 17: 305-319.
6. Gold-von Simson, G., Goldberg, J.D., Rolnitzky, L.M., Mull, J., Leyne, M., Voustianiouk, A., Slaugenhaupt, S.A. and Axelrod, F.B. 2009. Kinetin in familial dysautonomia carriers: implications for a new therapeutic strategy targeting mRNA splicing. Pediatr. Res. 65: 341-346.
7. Axelrod, F.B., Hilz, M.J., Berlin, D., Yau, P.L., Javier, D., Sweat, V., Bruehl, H. and Convit, A. 2010. Neuroimaging supports central pathology in familial dysautonomia. J. Neurol. 257: 198-206.
8. Audo, I., Bujakowska, K., Mohand-Saïd, S., Tronche, S., Lancelot, M.E., Antonio, A., Germain, A., Lonjou, C., Carpentier, W., Sahel, J.A., Bhattacharya, S. and Zeitz, C. 2011. A novel DFNB31 mutation associated with Usher type 2 syndrome showing variable degrees of auditory loss in a consanguineous Portuguese family. Mol. Vis. 17: 1598-1606.

CHROMOSOMAL LOCATION

Genetic locus: Lrrc19 (mouse) mapping to 4 C5.

PRODUCT

LRRC19 siRNA (m) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 µM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see LRRC19 shRNA Plasmid (m): sc-149058-SH and LRRC19 shRNA (m) Lentiviral Particles: sc-149058-V as alternate gene silencing products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 µl of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 µl of RNAse-free water makes a 10 µM solution in a 10 µM Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

LRRC19 siRNA (m) is recommended for the inhibition of LRRC19 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor LRRC19 gene expression knockdown using RT-PCR Primer: LRRC19 (m)-PR: sc-149058-PR (20 µl). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.